结核必治丸治疗小鼠结核病模型的疗效研究(英文)

Therapeutic effects of Bizhi pills in a murine model of mycobacterium tuberculosis infection

目的研究中药结核必治丸治疗小鼠结核病的药效。方法用结核分枝杆菌标准株 H37Rv 尾静脉注射昆明小鼠后,将小鼠随机分成 3 组,雌雄各半,在感染第 2 天分别用生理盐水(A)、利福平(B)和结核必治丸(C)治疗;治疗 3 个月和 4 个月,分别取肺、肝和脾,观察其病理改变、称取重量、做菌落计数。结果药物治疗3个月,C 组小鼠肺脏病理均明显轻于其他两组。C 组雌性小鼠肺脏菌落数比 A 组减少 4 倍,而 B 组肺脏菌落数比 C 组减少 8.5 倍。C 组雌性小鼠脾脏菌落数比 A 组的略为减少但无显著差别,而 B 组比 C 组减少 6.7 倍。C 组雄性小鼠脾脏菌落数比 A 组减少 3.8 倍(P <0.05),略高于 B 组,但与 B 组无差别。药物治疗 4 个月,C 组小鼠体重超过 A 组,但无显著意义。C 组小鼠肺脏指数显著低于 A 组(P <0.05),与 B 组无显著差别。C 组小鼠肺脏病理与 B 组表现相似,均有 4 例未见明显病变,而明显轻于 A 组。C 组雌性小鼠肺脏菌落数和脾脏菌落数显著低于 A 组(P <0.01),与 B 组则无显著差别(P >0.05);C 组雌性小鼠肺脏菌落数比 A 组减少 4 倍,而B组肺脏菌落数减少 6 倍;C 组雌性小鼠脾脏菌落数比 A 组减少 10 倍。C 组雄性小鼠肺脏菌落数比 A 组减少3 倍,脾脏菌落数比 A 组减少 2 倍,而 B 组肺脏菌落数比 A 组减少 14 倍,脾脏菌落数比 A 组减少 7 倍(P <0.01)。结论结核必治丸治疗小鼠结核病有一定的疗效。

[Objective] To study the therapeutic effects of Bizhi pills in Mycobacterium tuberculosis infection. [Methods] Kunming mice were infected by intravenous injection of Mycobacterium tuberculosis strain H37Rv in a tail vein and were subsequently treated with normal saline （group A）, Rifampin （group B） or Bizhi pills （group C）. The lungs, livers and spleens were taken and their pathological changes, weight and number of Mycobacterium tuberculosis colony were examined in 3 and 4 months of treatment respectively. [Results] In 3 months of treatment, lung lesion in group C was lighter than that in the others. The number of bacteria in the lungs of the female mice in group C was remarkably smaller than that in group A with a decrease of 4 times （P 〈0.05）, but the number of bacteria in the lungs of the female mice in group B was remarkably less than that in group C with a decrease of 8.5 times. The number of bacteria in the spleens of the female mice in group C was less than that in group A but there was no significant difference. The number of bacteria in the spleens of the female mice in group B was less than that in group C with a decrease of 6.7 times. The number of bacteria in the spleens of the male mice in group C was remarkably less than that in group A with a decrease of 3.8 times （P 〈0.05）, more than that in group B but without significant difference. In 4 months of treatment, weight of mice in group C was heavier than that in group A, but the difference was not significant. Indexes of the lungs in group C were markedly lower than those in group A, higher than those in group B without significant difference. Lung lesion in group C was similar to that in group B, and lighter than that in group A. The numbers of bacteria in the lungs and spleens of the female mice in group C were remarkably less than those in group A with a decrease of 4 times and 10 times, respectively （P 〈0.01）; but the numbers of bacteria in the lungs of the female mice in group B decreased by 6 times. The numbers of bacteria in the lungs and spleens of the male mice in group C were less than those in group A with a decrease of 3 times and 2 times, respectively. However, the numbers of bacteria in the lungs and spleens of the male mice in group B decreased by 14 times and 7 times, respectively （P 〈0.01）. [Conclusion] The therapeutic efficacy of Bizhi pills is significantly stronger than that of control group in mice with Mycobacterium tuberculosis infection, but inferior to Rifampin.